German gatekeepers nix GSK’s lupus drug Benlysta

GlaxoSmithKline's ($GSK) Benlysta can't catch a break from European gatekeepers. First, the U.K.'s cost-effectiveness watchdog rejected the lupus treatment, despite a discount scheme. Now, German…
Read the full story: News